Source: financialexpress.com
Tecfidera is still one of Cambridge, Massachusetts-based Biogen’s best-selling drugs. But reportedly, the company’s revenues from it have dropped because of generic competition.
According to a report by news agency Reuters, the justices turned away Biogen’s appeal of a lower court’s decision to invalidate the patent in a ruling that helped clear the way for Mylan’s generic version of Tecfidera.